Andrew Kader

Title(s)Professor Of Clinical, Urology
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. A. Karim Kader is one of the most experienced surgeons in the United States performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He received his undergraduate, doctorate of philosophy, and medical degrees from the University of British Columbia and completed his urology residency at the University of Toronto. He completed a urologic oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Kader holds several patents for genetic discoveries that hold significant promise for early detection and prevention of prostate cancer. He is the principal investigator for numerous clinical research projects and has published extensively. His research interests include genetic markers of risk and outcome in urologic cancer.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials. Urol Oncol. 2022 05; 40(5):199.e15-199.e21. Javier-DesLoges J, Nelson TJ, Murphy JD, McKay RR, Stewart TF, Kader AK, Derweesh I, Martinez ME, Rose BS. PMID: 35431133; PMCID: PMC10441556.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    2. Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer. J Natl Cancer Inst. 2022 04 11; 114(4):600-608. Kotha NV, Kumar A, Qiao EM, Qian AS, Voora RS, Nalawade V, Karim Kader A, McKay RR, Stewart TF, Rose BS. PMID: 34918091; PMCID: PMC9002275.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance. J Natl Compr Canc Netw. 2022 02; 20(2):151-159. Courtney PT, Deka R, Kotha NV, Cherry DR, Salans MA, Nelson TJ, Kumar A, Luterstein E, Yip AT, Nalawade V, Parsons JK, Kader AK, Stewart TF, Rose BS. PMID: 35130495; PMCID: PMC10399925.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    4. Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review. Cancers (Basel). 2021 Dec 24; 14(1). Walia AS, Sweis RF, Agarwal PK, Kader AK, Modi PK. PMID: 35008237; PMCID: PMC8750958.
      View in: PubMed   Mentions: 2  
    5. Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. Cancer. 2022 02 15; 128(4):770-777. Javier-DesLoges J, Nelson TJ, Murphy JD, McKay RR, Pan E, Parsons JK, Kane CJ, Kader AK, Derweesh IH, Nodora J, Patel SP, Martinez ME, Rose BS. PMID: 34806168.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    6. Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. Am J Epidemiol. 2021 10 01; 190(10):2064-2074. Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. PMID: 34023874; PMCID: PMC8576386.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men. Cancer. 2021 12 01; 127(23):4403-4412. Courtney PT, Deka R, Kotha NV, Cherry DR, Salans MA, Nelson TJ, Kumar A, Luterstein E, Yip AT, Nalawade V, Parsons JK, Kader AK, Stewart TF, Rose BS. PMID: 34347291.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urol Oncol. 2021 02; 39(2):130.e1-130.e7. Ghali F, Daly WC, Hansen M, Hayn M, Sammon J, Beaule LT, Sarkar R, Murphy J, Kader AK, Derweesh I, Rose B, Ryan ST. PMID: 33121914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560. Crawford ED, Hafron JM, Tagawa ST, Twardowski PW, Harris RG, Moul JW, Keane TE, Concepcion RS, Higano CS, Gordan LN, Petrylak DP, Cross CK, Kader AK, Shore ND. PMID: 33090917.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020 10; 27(5):10352-10362. Crawford ED, Andriole G, Freedland SJ, Garnick M, Gomella LG, Henderson J, Higano CT, Kader AK, Kane C, Keane TE, Koo PJ, Petrylak DP, Reiter RE, Slovin SF, Yu EY. PMID: 33049187.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis. 2020 12; 23(4):689-695. Sarkar RR, Patel SH, Parsons JK, Deka R, Kumar A, Einck JP, Mundt AJ, Kader AK, Kane CJ, Riviere P, McKay R, Murphy JD, Rose BS. PMID: 32513967.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. Prostate Cancer Prostatic Dis. 2020 12; 23(4):581-588. Deka R, Parsons JK, Simpson DR, Riviere P, Nalawade V, Vitzthum LK, Kader AK, Kane CJ, Rock CS, Murphy JD, Rose BS. PMID: 32327702.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. PMID: 32135513.
      View in: PubMed   Mentions: 211     Fields:    Translation:Humans
    14. Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice. Rev Urol. 2020; 22(4):152-158. Gaylis F, Bree KK, Dato P, Andriole GL, Kane CJ, Kader AK. PMID: 33927572; PMCID: PMC8058920.
      View in: PubMed   Mentions:
    15. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750. Crawford ED, Twardowski PW, Concepcion RS, Hafron JM, Harris RG, Moul JW, Gordan LN, Petrylak DP, Atkinson SN, Boldt-Houle DM, Keane TE, Higano CS, Henderson RJ, Kader AK, Hussain MH, Shore ND. PMID: 31580749.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Germline genetics in localized prostate cancer. Curr Opin Urol. 2019 07; 29(4):326-333. Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. PMID: 31116139.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    17. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med. 2019 06 01; 179(6):812-819. Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D'Amico AV, Nguyen PL, Hulley BJ, Einck JP, Mundt AJ, Kane CJ, Murphy JD, Rose BS. PMID: 31058923; PMCID: PMC6503564.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    18. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 08; 76(2):238-243. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. PMID: 31103391.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    19. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1068-1076. Bryant AK, McKay RR, Kader AK, Parsons JK, Einck JP, Kane CJ, Mundt AJ, Murphy JD, Rose BS. PMID: 30543857.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. PMID: 30181416.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    21. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1188-1193. Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS. PMID: 29891203.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    22. Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. Am J Surg Pathol. 2018 Jan; 42(1):e1-e10. Leivo MZ, Sahoo D, Hamilton Z, Mirsadraei L, Shabaik A, Parsons JK, Kader AK, Derweesh I, Kane C, Hansel DE. PMID: 29076872.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. PMID: 28982750.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    24. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. Arch Pathol Lab Med. 2018 Feb; 142(2):168-177. Mirsadraei L, Hodkoff A, Jones K, Shabaik A, Kader AK, Saenz CC, Montironi R, Tacha DE, Fadare O, Hansel DE. PMID: 28795841.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol. 2018 10; 36(10):440-447. Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD. PMID: 28755959.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCellsCTClinical Trials
    26. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. Urol Oncol. 2017 11; 35(11):663.e1-663.e7. Gaylis FD, Choi JE, Hamilton Z, Dato P, Cohen E, Calabrese R, Prime H, Rosenbaum A, Kader AK. PMID: 28736250.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    27. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review? Urology. 2017 04; 102:7-16. Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. PMID: 27769917.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. PMID: 27697976; PMCID: PMC5379654.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    29. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J Magn Reson Imaging. 2017 02; 45(2):323-336. Brunsing RL, Schenker-Ahmed NM, White NS, Parsons JK, Kane C, Kuperman J, Bartsch H, Kader AK, Rakow-Penner R, Seibert TM, Margolis D, Raman SS, McDonald CR, Farid N, Kesari S, Hansel D, Shabaik A, Dale AM, Karow DS. PMID: 27527500; PMCID: PMC5222783.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    30. Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men. Cancer. 2016 Nov 15; 122(22):3564-3575. Turner AR, Lane BR, Rogers D, Lipkus I, Weaver K, Danhauer SC, Zhang Z, Hsu FC, Noyes SL, Adams T, Toriello H, Monroe T, McKanna T, Young T, Rodarmer R, Kahnoski RJ, Tourojman M, Kader AK, Zheng SL, Baer W, Xu J. PMID: 27433786; PMCID: PMC5247411.
      View in: PubMed   Mentions: 3     Fields:    
    31. Weight Loss Following Radical Cystectomy for Bladder Cancer: Characterization and Effect on Survival. Clin Genitourin Cancer. 2017 02; 15(1):86-92. McDonald ML, Liss MA, Nseyo UU, Gal DB, Kane CJ, Kader AK. PMID: 27460433.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate. 2016 09; 76(12):1120-9. Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. PMID: 27197965; PMCID: PMC5501387.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    33. Risk factors for infectious readmissions following radical cystectomy: results from a prospective multicenter dataset. Ther Adv Urol. 2016 Jun; 8(3):167-74. Hemal S, Krane LS, Richards KA, Liss M, Kader AK, Davis RL. PMID: 27247626; PMCID: PMC4872190.
      View in: PubMed   Mentions: 5  
    34. Trends in Metastatic Breast and Prostate Cancer. N Engl J Med. 2016 02 11; 374(6):594-5. Gaylis FD, Choi J, Kader AK. PMID: 26863369.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Sentinel lymph node biopsy in bladder cancer: Systematic review and technology update. Indian J Urol. 2015 Jul-Sep; 31(3):170-5. Liss MA, Noguchi J, Lee HJ, Vera DR, Kader AK. PMID: 26166959; PMCID: PMC4495490.
      View in: PubMed   Mentions: 3  
    36. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial. Prostate. 2015 Sep; 75(12):1322-8. Liss MA, Xu J, Chen H, Kader AK. PMID: 25982801.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    37. Reply: To PMID 25530379. Urology. 2015 Jan; 85(1):171. Kader AK, Liss MA, Xu J, Fleshner NE. PMID: 25530381.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. Urology. 2015 Jan; 85(1):165-70. Kader AK, Liss MA, Trottier G, Kim ST, Sun J, Zheng SL, Chadwick K, Lockwood G, Xu J, Fleshner NE. PMID: 25530379; PMCID: PMC5398897.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol. 2015 Jan; 193(1):75-9. Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK. PMID: 25066872.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    40. Minimally invasive cystectomy is associated with improved perioperative patient safety outcomes compared with open cystectomy in a national cohort. Urology. 2014 Aug; 84(2):314-9. Cohen SA, Mirheydar HS, Parsons JK, Palazzi KL, Liss MA, Chang DC, Kane CJ, Kader AK. PMID: 24958477.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. Reply: To PMID 24958477. Urology. 2014 Aug; 84(2):319-20. Cohen SA, Mirheydar HS, Parsons JK, Palazzi KL, Liss MA, Chang DC, Kane CJ, Kader AK. PMID: 24958489.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Primary mucin-producing urothelial-type adenocarcinoma of the prostatic urethra diagnosed on TURP: a case report and review of literature. BMC Urol. 2014 May 22; 14:39. Sebesta EM, Mirheydar HS, Parsons JK, Wang-Rodriguez J, Kader AK. PMID: 24885582; PMCID: PMC4059493.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Robot-assisted triple neurectomy for iatrogenic inguinal pain: a technical note. Acta Neurochir (Wien). 2014 Jan; 156(1):171-5. Mahan MA, Kader AK, Brown JM. PMID: 24026228.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    44. Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol. 2013 Aug; 27(8):1046-50. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK. PMID: 23517015.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    45. Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients. BJU Int. 2013 Aug; 112(4):E290-4. Kader AK, Richards KA, Krane LS, Pettus JA, Smith JJ, Hemal AK. PMID: 23815802.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    46. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013 Jul 01; 119(13):2405-12. Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Grönberg H, Isaacs WB, Xu J. PMID: 23609948; PMCID: PMC3863778.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    47. Guest editorial: robotic techniques in urologic oncology. World J Urol. 2013 Jun; 31(3):429. Kane CJ, Kader AK. PMID: 23595604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Robotic-assisted laparoscopic radical cystectomy: history, techniques and outcomes. World J Urol. 2013 Jun; 31(3):489-97. Liss MA, Kader AK. PMID: 23512230.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    49. Is robot-assisted radical cystectomy justified in the elderly? A comparison of robotic versus open radical cystectomy for bladder cancer in elderly ≥75 years old. J Endourol. 2012 Oct; 26(10):1301-6. Richards KA, Kader AK, Otto R, Pettus JA, Smith JJ, Hemal AK. PMID: 22582706.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    50. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012 Dec; 62(6):953-61. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. PMID: 22652152; PMCID: PMC3568765.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    51. Utility of genome-wide association study findings: prostate cancer as a translational research paradigm. J Intern Med. 2012 Apr; 271(4):344-52. Turner AR, Kader AK, Xu J. PMID: 22272820; PMCID: PMC3753782.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    52. A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol. 2012 Jan; 36(1):71-83. Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J. PMID: 22890972; PMCID: PMC3791431.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    53. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma. J Surg Oncol. 2012 Mar; 105(3):258-60. Krane LS, Kader AK, Levine EA. PMID: 22271499.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    54. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate. 2012 Mar; 72(4):376-85. Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J. PMID: 21671247; PMCID: PMC3366362.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    55. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. PMID: 21426474.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    56. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. Prostate. 2010 Dec 01; 70(16):1729-38. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J, Sun J. PMID: 20564319; PMCID: PMC3013361.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    57. Percutaneous radiofrequency ablation does not affect glomerular filtration rate. J Endourol. 2010 Oct; 24(10):1687-91. Pettus JA, Werle DM, Saunders W, Hemal A, Kader AK, Childs D, Zagoria RJ. PMID: 20818985.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    58. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate. 2011 Mar 01; 71(4):421-30. Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y, Turner AR, Jin T, Zhang Z, Adolfsson J, Wiklund F, Zheng SL, Isaacs WB, Grönberg H, Xu J. PMID: 20878950; PMCID: PMC3025084.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    59. Robot assisted laparoscopic pelvic lymphadenectomy at the time of radical cystectomy rivals that of open surgery: single institution report. Urology. 2010 Dec; 76(6):1400-4. Richards KA, Hemal AK, Kader AK, Pettus JA. PMID: 20350755.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    60. Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev. 2010 Apr; 19(4):1083-8. Hsu FC, Sun J, Zhu Y, Kim ST, Jin T, Zhang Z, Wiklund F, Kader AK, Zheng SL, Isaacs W, Grönberg H, Xu J. PMID: 20332264; PMCID: PMC2852494.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    61. Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens. Urology. 2010 May; 75(5):1116-20. Richards KA, Parks GE, Badlani GH, Kader AK, Hemal AK, Pettus JA. PMID: 20080289.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2136-40. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Grönberg H, Isaacs WB. PMID: 20080650; PMCID: PMC2836698.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    63. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate. 2009 Oct 01; 69(14):1565-72. Xu J, Sun J, Kader AK, Lindström S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Grönberg H. PMID: 19562736; PMCID: PMC2793526.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    64. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009 Aug 01; 69(11):1195-205. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W. PMID: 19434657; PMCID: PMC2852875.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    65. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008 Feb 28; 358(9):910-9. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. PMID: 18199855.
      View in: PubMed   Mentions: 301     Fields:    Translation:HumansCells
    66. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007 May 01; 13(9):2614-20. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. PMID: 17473191.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    67. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007 Mar; 177(3):855-60; discussion 860-1. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. PMID: 17296358.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    68. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006 Dec 15; 66(24):11644-8. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. PMID: 17178858.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    69. Nephroureterostomy-drained percutaneous nephrolithotomy: modification combining safety with decreased morbidity. J Endourol. 2004 Feb; 18(1):29-32. Kader AK, Finelli A, Honey RJ. PMID: 15006049.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Andrew's Networks
    Concepts (225)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (40)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California